- Language: English
- 346 Pages
- Published: August 2012
MRSA Partnering 2009-2014
- Published: August 2014
- Region: Global
- 100 pages
The MRSA Partnering 2009-2014 provides understanding and access to the MRSA partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of MRSA partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors MRSA technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 50 links to online copies of actual MRSA deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of MRSA partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in MRSA partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading MRSA deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of MRSA partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of MRSA technologies and products.
MRSA Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to MRSA trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
Trends in MRSA dealmaking in the biopharma industry since 2009
Access to summary headline, upfront, milestone and royalty data
The leading MRSA deals by value since 2009
In MRSA Partnering 2009-2014, the available deals are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. SHOW LESS READ MORE >
Chapter 1 – Introduction
Chapter 2 – Trends in MRSA partnering
2.2. MRSA partnering over the years
2.3. Bigpharma MRSA dealmaking activity
2.4. MRSA partnering by deal type
2.5. MRSA partnering industry sector
2.6. MRSA partnering by stage of development
2.7. MRSA partnering by technology type
2.8. Disclosed financial deal terms for MRSA partnering
2.8.1 MRSA headline values
2.8.2 MRSA upfront payments
2.8.3 MRSA milestone payments
2.8.4 MRSA royalty rates
Chapter 3 – Leading MRSA deals
3.2. Top MRSA deals by value
3.3. Top MRSA deals involving bigpharma
Chapter 4 – Dealmaking directory
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type
Diagnostic - companion
In vitro models
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendix 1 – Deal type definitions
About Wildwood Ventures
Recent titles from CurrentPartnering
Order Form – Reports
Table of figures
Figure 1: MRSA partnering since 2009
Figure 2: Bigpharma – top 50 – MRSA deals 2009 to 2011
Figure 3: Bigpharma MRSA deal frequency – 2009 to 2011
Figure 4: MRSA partnering by deal type since 2009
Figure 5: MRSA partnering by industry sector since 2009
Figure 6: MRSA partnering by stage of development since 2009
Figure 7: MRSA partnering by technology type since 2009
Figure 8: MRSA deals with a headline value
Figure 9: MRSA deals with upfront payment values
Figure 10: MRSA deals with milestone payments
Figure 11: MRSA deals with royalty rates, %
Figure 12: Top MRSA deals by value since 2009
Figure 13: Top MRSA deals signed by bigpharma value since 2009
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co